Lannett remains optimistic about the “durable” opportunities offered by the respiratory generics and biosimilar insulins in its pipeline, despite a downturn in its financial third quarter ended 31 March 2021 that saw its sales fall by 22.2% to $112.4m.
Lannett Bets On Respiratory And Insulins Pipeline As Sales Falter
Advair And Flovent Rivals And Biosimilar Insulins Among ‘Durable’ Opportunities
Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.
